Maribavir isomers, compositions, methods of making and methods of using

Abstract

The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.

1 - 24 . (canceled) 
     
     
         25 . A method for treatment of a herpes viral infection in a patient in need thereof comprising orally administering to the patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of the compound, in an amount of 400 mg twice a day,
 wherein: 
 i) the compound or isomer is administered as a composition, 
 ii) the composition is an immediate release formulation, and 
 iii) the patient is a stem cell transplant recipient. 
 
     
     
         26 . The method according to  claim 25 , wherein the herpes viral infection is cytomegalovirus infection or disease. 
     
     
         27 . The method according to  claim 26 , wherein the compound is administered to the patient under fasted conditions. 
     
     
         28 . The method according to  claim 26 , wherein the compound is administered as a composition comprising a therapeutically acceptable adjuvant, excipient, or carrier medium. 
     
     
         29 . A method for treatment of a herpes viral infection in a patient in need thereof comprising orally administering to the patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound, in an amount of 400 mg twice a day,
 wherein: 
 i) the compound or isomer is administered as a composition, 
 ii) the composition is an immediate release formulation, and 
 iii) the patient is a kidney transplant recipient. 
 
     
     
         30 . The method according to  claim 29 , wherein the herpes viral infection is cytomegalovirus infection or disease. 
     
     
         31 . The method according to  claim 30 , wherein the compound is administered to the patient under fasted conditions. 
     
     
         32 . The method according to  claim 30 , wherein the compound is administered as a composition comprising a therapeutically acceptable adjuvant, excipient, or carrier medium. 
     
     
         33 . A method for treatment of a herpes viral infection in a patient in need thereof comprising orally administering to the patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound, in an amount of 400 mg twice a day,
 wherein: 
 i) the compound or isomer is administered as a composition, 
 ii) the composition is an immediate release formulation, and 
 iii) the patient is a liver transplant recipient. 
 
     
     
         34 . The method according to  claim 33 , wherein the herpes viral infection is cytomegalovirus infection or disease. 
     
     
         35 . The method according to  claim 34 , wherein the compound is administered to the patient under fasted conditions. 
     
     
         36 . The method according to  claim 34 , wherein the compound is administered as a composition comprising a therapeutically acceptable adjuvant, excipient, or carrier medium. 
     
     
         37 . The method according to any one of  claims 25 - 36 , wherein the compound administered is 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole.